CORC

浏览/检索结果: 共6条,第1-6条 帮助

已选(0)清除 条数/页:   排序方式:
Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC) 会议论文
44th Congress of the European-Society-for-Medical-Oncology (ESMO), SEP 27-OCT 01, 2019
作者:  Ardizzoni, A.;  Azevedo, S.;  Rubio Viquiera, B.;  Rodriguez Abreu, D.;  Alatorre-Alexander, J.
收藏  |  浏览/下载:16/0  |  提交时间:2019/12/31
Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial 期刊论文
ANNALS OF ONCOLOGY, 2018, 卷号: 29
作者:  Cseh, A.;  Felip, E.;  Bender, S.;  Goss, G. D.;  Cobo, M.
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/05
Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11
作者:  Goss, G.;  Felip, E.;  Cobo, M.;  Lu, S.;  Syrigos, K.
收藏  |  浏览/下载:9/0  |  提交时间:2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 会议论文
作者:  Li, W.;  Gadgeel, S. M.;  Soria, J. C.;  Felip, E.;  Cobo, M.
收藏  |  浏览/下载:6/0  |  提交时间:2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 期刊论文
EUROPEAN JOURNAL OF CANCER, 2017, 卷号: 72
作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Soria, J. C.;  Syrigos, K.
收藏  |  浏览/下载:11/0  |  提交时间:2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers 期刊论文
ANNALS OF ONCOLOGY, 2016, 卷号: 27
作者:  Lee, K. H.;  Soria, J-C.;  Felip, E.;  Cobo, M.;  Lu, S.
收藏  |  浏览/下载:6/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace